Live from ClinicalTrials.gov + Open Targets, fetched 2026-11-12 02:09 UTC. Every row links to its source record.
Postmortem · what the sponsor and named sources said, kept apart from what merely happened at the same time
Closed-loop Control of Glucose Levels (Artificial Pancreas) for 5 Days in Adults With Type 1 Diabetes
NCT02488616 · Institut de Recherches Cliniques de Montreal · PHASE2 · withdrawn · last registry update 2018-01-31 · Decision brief
No research has been run for this trial yet, so only the registry's own reason and the timeline are shown.
What was said, and by whom
Stated is the sponsor's own words; Reported is a named third party. The category is our label from a fixed list; the quote is the evidence.
| Kind | Quote | Our category | Source |
|---|---|---|---|
| Stated | “Medtronic support terminated” | – | Registry record, Institut de Recherches Cliniques de Montreal |
Also happening at the time. Not shown to be a cause.
Registry events on other trials of drugs against INSR within 12 months either side of this trial's last update, live from ClinicalTrials.gov. Nothing here was stated as a reason.
- 2019-01-16Also stopped (withdrawn): University of Texas Southwestern Medical Center, Levemir (Detemir) and Novolog (Aspart) Insulin (NCT00906529)
- 2019-01-15Results posted on the registry: Cairo University, regular insulin + 70/30 insulin (NCT01855243)
- 2018-12-07Results posted on the registry: Novo Nordisk A/S, insulin degludec/insulin aspart + biphasic insulin aspart (NCT02762578)
- 2018-11-28Results posted on the registry: The University of Texas Health Science Center, Houston, Metformin + Insulin (NPH and Regular) (NCT00678080)
- 2018-11-14Phase 3 first posted: Eli Lilly and Company, LY900014 + Insulin Lispro (NCT03740919)
- 2018-11-09Phase 3 first posted: Emory University, IDegLira + Insulin Degludec (U-100) (NCT03737240)
- 2018-11-01Results posted on the registry: Eli Lilly and Company, Insulin Peglispro + Insulin Glargine (NCT02197520)
- 2018-10-23Results posted on the registry: Novo Nordisk A/S, insulin degludec/liraglutide + insulin glargine (NCT02773368)
- 2018-10-19Results posted on the registry: Eli Lilly and Company, Insulin Peglispro (NCT01995526)
- 2018-09-28Results posted on the registry: Novo Nordisk A/S, Insulin degludec/insulin aspart + Insulin glargine (NCT02906917)
- 2018-09-14Results posted on the registry: Sanofi, Insulin glargine, 300U/mL + Insulin degludec, 100 U/mL (NCT02738151)
- 2018-09-13Results posted on the registry: University Health Network, Toronto, ASP7487, Velcade, Dexamethasone (NCT01672736)
- 2018-09-13Also stopped (terminated): University Health Network, Toronto, ASP7487, Velcade, Dexamethasone (NCT01672736)
- 2018-09-11Results posted on the registry: Novo Nordisk A/S, insulin degludec/insulin aspart + biphasic insulin aspart (NCT02648217)
- 2018-09-10Results posted on the registry: Merck Sharp & Dohme LLC, Ertugliflozin 5 mg + Ertugliflozin 15 mg (NCT02033889)
- 2018-09-10Also stopped (terminated): Novo Nordisk A/S, Insulin detemir + Insulin NPH (NCT02131272)
- 2018-09-05Also stopped (terminated): Novo Nordisk A/S, inhaled human insulin + insulin detemir (NCT00322257)
- 2018-08-27Also stopped (terminated): University Hospital, Strasbourg, France, Metformin + Rapid acting analog insulin Intermediate acting NPH Insulin (NCT01756105)
- 2018-08-20Results posted on the registry: Sanofi, HOE901-U300 (Insulin Glargine 300 U/ml) + Lantus (Insulin Glargine 100 U/ml) (NCT02688933)
- 2018-08-10Results posted on the registry: Novo Nordisk A/S, Faster-acting insulin aspart + insulin aspart (NCT02500706)
- 2018-07-17Results posted on the registry: Montefiore Medical Center, Insulin Detemir mixed with RAI injection + Insulin Detemir and RAI injection (NCT00564395)
- 2018-07-09Results posted on the registry: Novo Nordisk A/S, insulin degludec/liraglutide + liraglutide (NCT01676116)
- 2018-06-27Results posted on the registry: Emory University, Sitagliptin + Placebo (NCT02741687)
- 2018-05-18Phase 3 first posted: Sanofi, INSULIN GLARGINE/LIXISENATIDE (HOE901/AVE0010) + INSULIN GLARGINE (HOE901) (NCT03529123)
- 2018-05-03Results posted on the registry: Eli Lilly and Company, LY2605541 + Human Insulin NPH (NCT01790438)
What is not public
- Internal portfolio and board discussions
- Unpublished trial data and interim analyses
- Terms of any partner or licence decision